Michael Brophy, the Chief Financial Officer of Natera Inc (NTRA, Financial), has sold 1,378 shares of the company on April 2, 2024, according to a recent SEC filing. The transaction was executed at an average price of $92.62 per share, resulting in a total value of $127,673.36.
Natera Inc is a pioneer in the field of genetic testing and diagnostics, offering a range of services including prenatal testing, cancer screening, and organ health testing. The company leverages advanced technology to provide accurate and comprehensive results for patients and healthcare providers.
Over the past year, Michael Brophy has sold a total of 87,228 shares of Natera Inc and has not made any purchases of the stock. This latest transaction continues a trend of insider selling at the company, with a total of 73 insider sells and no insider buys occurring over the past year.
The insider transaction history suggests a pattern of insider sales that could be of interest to current and potential investors. It is important to note that insider selling does not always indicate a lack of confidence in the company; it can also reflect personal financial management decisions.
On the valuation front, Natera Inc's shares were trading at $92.62 on the day of the transaction, giving the company a market capitalization of $11.153 billion. The stock's price-to-GF-Value ratio stands at 1.43, with the GF Value estimated at $64.56. According to this metric, Natera Inc is currently significantly overvalued.
The GF Value is determined by considering historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. Additionally, a GuruFocus adjustment factor is applied based on the company's historical returns and growth, along with future business performance estimates provided by Morningstar analysts.
Investors and analysts often monitor insider transactions as they can provide insights into the insider's view of the company's stock value and future prospects. However, it is also crucial to consider the broader market conditions and the company's financial performance when evaluating the significance of insider trading activity.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
